SCHEDULE 13G/A: BB Biotech AG Reports Reduced Stake in Esperion Therapeutics, Inc. Below 5%

BB Biotech AG, through its wholly-owned subsidiary Biotech Target N.V., has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 4.89973% of Esperion Therapeutics, Inc.'s common stock as of March 4, 2025.

Summary

• BB Biotech AG, a Swiss entity, and its wholly-owned subsidiary, Biotech Target N.V. (Curacao), have filed Amendment No. 13 to Schedule 13G.
• The filing pertains to their beneficial ownership in Esperion Therapeutics, Inc. Common Stock (CUSIP: 29664W105).
• As of March 4, 2025, the aggregate amount beneficially owned by the reporting persons is 9,694,064 shares.
• This represents 4.89973% of Esperion Therapeutics, Inc.'s common stock, indicating a stake below the 5% threshold.
• Both BB Biotech AG and Biotech Target N.V. share voting and dispositive power over all 9,694,064 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual, routine regulatory filing (Schedule 13G Amendment) reporting beneficial ownership, which inherently carries a neutral sentiment. It does not contain positive or negative operational or financial news about the issuer.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment firm in a biotechnology company. It does not provide specific insights into broader industry trends beyond indicating continued investment interest in the biotechnology sector, albeit with a reported stake now below 5%.

Related Party Transactions

• The filing indicates that Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG, and the beneficial ownership is reported jointly by both entities, reflecting a standard parent-subsidiary relationship for investment purposes.

Stakeholder Impact

• Primarily informs existing and potential shareholders about the ownership structure of Esperion Therapeutics, Inc., specifically the stake held by BB Biotech AG and its subsidiary, which is now reported below the 5% threshold.

Key Dates

Keywords

Esperion Therapeutics, BB Biotech AG, Biotech Target N.V., Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, SEC Filing